Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment

References

• World Health Organization [webpage on the Internet]Hepatitis C Fact Sheet2017 Available from: http://www.who.int/mediacentre/factsheets/fs164/en/Accessed July 2017
   Google Scholar
• AnsaldiFOrsiASticchiLBruzzoneBIcardiGHepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapyWorld J Gastroenterol201420299633965225110404
   PubMed Web of Science ®Google Scholar
• Abou RachedAAbou KheirSSabaJAmmarWEpidemiology of hepatitis B and hepatitis C in LebanonArab J Gastroenterol2016171293327032492
   PubMed Web of Science ®Google Scholar
• Abou RachedAAbou KheirSSabaJYaghiCAmmarWPrevalence of hepatitis C and fibrosis stage per age group in Lebanese populationGastroenterology Insights2017812327
   Web of Science ®Google Scholar
• Abou RachedAYaghiCKhalilLSabaJAmmarWPrevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groupsArab J Gastroenterol201718211411728579342
   PubMed Web of Science ®Google Scholar
• van der MeerAJVeldtBJFeldJJAssociation between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosisJAMA2012308242584259323268517
   PubMed Web of Science ®Google Scholar
• ReauNVekemanFWuEBaoYGonzalezYSPrevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapyHepatol Commun2017143945229404471
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatitis C virus infectionJ Hepatol201155224526421371579
   PubMed Web of Science ®Google Scholar
• LiangTJGhanyMGCurrent and future therapies for hepatitis C virus infectionN Engl J Med2013368201907191723675659
   PubMed Web of Science ®Google Scholar
• ReauNSJensenDMSticker shock and the price of new therapies for hepatitis C: is it worth it?Hepatology20145941246124924493069
   PubMed Web of Science ®Google Scholar
• NajafzadehMAnderssonKShrankWHCost-effectiveness of novel regimens for the treatment of hepatitis C virusAnn Intern Med2015162640741925775313
   PubMed Web of Science ®Google Scholar
• SimonTGChungRTThe new hepatitis C virus bottleneck: can delaying therapy be justified?Hepatology201562366666726058922
   PubMed Web of Science ®Google Scholar
• El KhouryACKlimackWKWallaceCRazaviHEconomic burden of hepatitis C-associated diseases in the United StatesJ Viral Hepat201219315316022329369
   PubMed Web of Science ®Google Scholar
• DavisGLAlterMJEl-SeragHPoynardTJenningsLWAging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progressionGastroenterology20101382513521521 e511e51619861128
   PubMed Web of Science ®Google Scholar
• GordonSCPockrosPJTerraultNAImpact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infectionHepatology20125651651166022610658
   PubMed Web of Science ®Google Scholar
• PyensonBFitchKIwasakiKConsequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver DiseaseNew York, NYMilliman, Inc2009
   Google Scholar
• ColvinHMMitchellAEInstitute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis InfectionHepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and CWashington (DC)National Academies Press(US)2010
   Google Scholar
• Deuffic-BurbanSSchwarzingerMObachDShould we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)J Hepatol201461171424650691
   PubMed Web of Science ®Google Scholar
• LiuSCiprianoLEHolodniyMGoldhaber-FiebertJDCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesPLoS One201383e5897523533595
   PubMed Web of Science ®Google Scholar
• ReinDBSmithBDWittenbornJSThe cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settingsAnn Intern Med2012156426327022056542
   PubMed Web of Science ®Google Scholar
• SroczynskiGEstebanEConrads-FrankALong-term effectiveness and cost-effectiveness of screening for hepatitis C virus infectionEur J Public Health200919324525319196737
   PubMed Web of Science ®Google Scholar
• TramarinAGennaroNCompostellaFAGalloCWendelaar BongaLJPostmaMJHCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populationsCurr Pharm Des200814171655166018673188
   PubMed Web of Science ®Google Scholar
• HaganLMYangZEhteshamiMSchinaziRFAll-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analysesJ Viral Hepat2013201284785724304454
   PubMed Web of Science ®Google Scholar
• YounossiZMSingerMEMirHMHenryLHuntSImpact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patientsJ Hepatol201460353053724269472
   PubMed Web of Science ®Google Scholar
• LeighJPBowlusCLLeistikowBNSchenkerMCosts of hepatitis CArch Intern Med2001161182231223711575980
   PubMedGoogle Scholar
• ShahBBWongJBThe economics of hepatitis C virusClin Liver Dis200610471773417164114
   PubMedGoogle Scholar
• DavisKLMitraDMedjedovicJBeamCRustgiVDirect economic burden of chronic hepatitis C virus in a United States managed care populationJ Clin Gastroenterol2011452e17e2420628308
   PubMed Web of Science ®Google Scholar
• NicholsGABellTJPedulaKLO’Keeffe-RosettiMMedical care costs among patients with established cardiovascular diseaseAm J Manag Care2010163e86e9320205493
   PubMed Web of Science ®Google Scholar
• DallTMZhangYChenYJQuickWWYangWGFogliJThe economic burden of diabetesHealth Aff (Millwood)201029229730320075080
   PubMed Web of Science ®Google Scholar
• LuoRGreenbergAStoneCDIncreasing volume but decreasing mortality of hospitalized hepatitis C patients in the United States, 2005 to 2011J Clin Gastroenterol201549762062725203363
   PubMed Web of Science ®Google Scholar
• XuFTongXLeidnerAJHospitalizations and costs associated with hepatitis C and advanced liver disease continue to increaseHealth Aff (Millwood)201433101728173525288416
   PubMed Web of Science ®Google Scholar
• WongJBMcQuillanGMMcHutchisonJGPoynardTEstimating future hepatitis C morbidity, mortality, and costs in the United StatesAm J Public Health200090101562156911029989
   PubMed Web of Science ®Google Scholar
• Nuno SolinisRArratibel UgartePRojoASanchez GonzalezYValue of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidenceInfect Dis Ther20165449150827783223
   PubMed Web of Science ®Google Scholar
• IgarashiATangWGuerraIMarieLCureSLoprestiMCost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in JapanCurr Med Res Opin2017331112127609424
   PubMed Web of Science ®Google Scholar
• McEwanPWardTWebsterSEstimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1bHepatol Res201646542343326440999
   PubMed Web of Science ®Google Scholar
• YounossiZMParkHSaabSAhmedADieterichDGordonSCCost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infectionAliment Pharmacol Ther201541654456325619871
   PubMed Web of Science ®Google Scholar
• NgVSaabSEffects of a sustained virologic response on outcomes of patients with chronic hepatitis CClin Gastroenterol Hepatol201191192393021699815
   PubMed Web of Science ®Google Scholar
• SingalAGVolkMLJensenDDi BisceglieAMSchoenfeldPSA sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virusClin Gastroenterol Hepatol201083280288288 e28119948249
   PubMed Web of Science ®Google Scholar
• LinthicumMTGonzalezYSMulliganKValue of expanding HCV screening and treatment policies in the United StatesAm J Manag Care2016226 Spec NoSP227SP23527266953
   PubMed Web of Science ®Google Scholar
• CacoubPGragnaniLComarmondCZignegoALExtrahepatic manifestations of chronic hepatitis C virus infectionDig Liver Dis201446Suppl 5S165S17325458776
   PubMedGoogle Scholar
• NegroFFortonDCraxiASulkowskiMSFeldJJMannsMPExtrahepatic morbidity and mortality of chronic hepatitis CGastroenterology201514961345136026319013
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGuidelines for the Screening, Care and Treatment of Persons with Hepatitis C InfectionGeneva, Switzerland2014
   Google Scholar
• MisurskiDAP0816: reduction in annual medical costs with early treatment of HCV using AbbVie 3D (ABT-450/ritonavir/ombitasvir and dasabuvir) +/− ribavirin in the United StatesJ Hepatol2015621S642
   Web of Science ®Google Scholar
• SemelaDBlachSBihlFKBruggmannPLavanchyDNegroFThe impact of time on a scenario to minimize complications of hepatitis C infectionHepatology201460912A
   Google Scholar
• ChhatwalJKanwalFRobertsMSDunnMACost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesAnn Intern Med2015162639740625775312
   PubMed Web of Science ®Google Scholar
• IgarashiATangWCureSCost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in JapanCurr Med Res Opin2017331110
   PubMed Web of Science ®Google Scholar
• SampJCPerryRPiercyJWoodRBaranRWPatient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in FranceClin Res Hepatol Gastroenterol201539330731425511922
   PubMed Web of Science ®Google Scholar
• ChhatwalJHeTLopez-OlivoMASystematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antiviralsPharmacoeconomics201634655156726748919
   PubMed Web of Science ®Google Scholar
• Gonzalez-GrandeRJimenez-PerezMGonzalez ArjonaCMostazo TorresJNew approaches in the treatment of hepatitis CWorld J Gastroenterol20162241421143226819511
   PubMed Web of Science ®Google Scholar
• El KhouryACVietriJPrajapatiGThe burden of untreated hepatitis C virus infection: a US patients’ perspectiveDig Dis Sci201257112995300322674399
   PubMed Web of Science ®Google Scholar
• ContiFBuonfiglioliFScuteriAEarly occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJ Hepatol201665472773327349488
   PubMed Web of Science ®Google Scholar
• ReigMMarinoZPerelloCUnexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJ Hepatol201665471972627084592
   PubMed Web of Science ®Google Scholar
• ANRS Collaborative Study Group on Hepatocellular CarcinomaLack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts)J Hepatol201665473474027288051
   PubMed Web of Science ®Google Scholar
• TheinHHYiQDoreGJKrahnMDEstimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regressionHepatology200848241843118563841
   PubMed Web of Science ®Google Scholar
• LiuSCiprianoLEHolodniyMOwensDKGoldhaber-FiebertJDNew protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysisAnn Intern Med2012156427929022351713
   PubMed Web of Science ®Google Scholar
• AlazawiWCunninghamMDeardenJFosterGRSystematic review: outcome of compensated cirrhosis due to chronic hepatitis C infectionAliment Pharmacol Ther201032334435520497143
   PubMed Web of Science ®Google Scholar
• RazaviHElkhouryACElbashaEChronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology20135762164217023280550
   PubMed Web of Science ®Google Scholar
• SingalAKSinghAJaganmohanSAntiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosisClin Gastroenterol Hepatol20108219219919879972
   PubMed Web of Science ®Google Scholar
• ThuluvathPJGuidingerMKFungJJJohnsonLBRayhillSCPelletierSJLiver transplantation in the United States, 1999–2008Am J Transplant2010104 Pt 21003101920420649
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGADVANCE Study TeamTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med2013368201878188723607594
   PubMed Web of Science ®Google Scholar
• FerenciPBernsteinDLalezariJABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVN Engl J Med2014370211983199224795200
   PubMed Web of Science ®Google Scholar
• FeldJJKowdleyKVCoakleyETreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171594160324720703
   PubMed Web of Science ®Google Scholar
• PoordadFHezodeCTrinhRABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisN Engl J Med2014370211973198224725237
   PubMed Web of Science ®Google Scholar